Slide 1: Innate Pharma: Long standing expertise in immunology
Innate Pharma Long standing expertise in immunology Investor and analyst event New York 3 October 2024
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Investor and Analyst Meeting
Investor and Analyst Meeting Strategic Overview and Outlook Hervé Brailly Chief Executive Officer ad interim, Chairman of the Executive Board Lacutamab Sonia Quaratino Chief Medical Officer ANKET® Eric Vivier Chief Scientific Officer ADC Yannis Morel Monalizumab Chief Operating Officer Upcoming Cata
Slide 4: Strategic Overview and Outlook
Strategic Overview and Outlook Hervé Brailly Chief Executive Officer Chairman of the Executive Board 4
Slide 5: Scientific innovation drives our strategy
Scientific innovation drives our strategy Leveraging our expertise in innate immunity and antibody engineering to develop novel, first-in-class therapies for cancer, advancing a diverse pipeline of proprietary and partnered assets with major biopharma companies Lacutamab ANKET® & ADC Monalizumab Pha
Slide 6: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Pre-Clinical Phase 1 Phase 2 Phase 3 IPH81 IPH5301 (CD73) Lacutamab (KIR3DL2) Monalizumab (NKG2A) Undisclosed Target Solid tumors CTCL Unresectable Stg III NSCLC Others IPH6501 (CD20-IL2v) Lacutamab (KIR3DL2) Undisclosed Targets B-NHL PTCL IPH62
Slide 7: Lacutamab
Lacutamab Sonia Quaratino Chief Medical Officer 7
Slide 8: Lacutamab | Clinical Trials
LACUTAMAB Lacutamab | Clinical Trials A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 Cutaneous T cell lymphoma TELLOMAK Phase 2 Trial Sézary syndrome Sézary syndrome N=56 Phase 2 ~90% KIR3DL2 Minimum of 2 prior therapies, including mogamulizumab 2025 expression ≥1% Mycos
Slide 9: TELLOMAK – Sézary syndrome Best Global Response (N=56)
LACUTAMAB TELLOMAK – Sézary syndrome Best Global Response (N=56) Best Global Response = 37.5% • 21 (37.5%) patients achieved Global Response, including 2 CR and 19 PR • Median time to Global Response: 2.8 months (range: 1-9) • Median Duration of Respones 12.3 months (5.2 - NE) Data cut-off (DCO): Ma
Slide 10: TELLOMAK – Sézary syndrome Efficacy results: PFS
LACUTAMAB TELLOMAK – Sézary syndrome Efficacy results in SS patients: PFS Progression Free Survival (PFS) PFS median (95% CI) 8.0 months (4.7-21.2) Alive without progression % (95% CI) • at 6 months 58.9 (43.3 - 71.5) • at 12 months 43.3 (27.3 - 58.2) • at 18 months 38.9 (22.9 - 54.7) Data cut-off (
Slide 11: TELLOMAK – Mycosis Fungoides Waterfall plot by KIR3DL2 Expression
LACUTAMAB TELLOMAK – Mycosis Fungoides Waterfall plot for Best Overall Response by KIR3DL2 Expression Level KIR3DL2 ≥ 1% (N=48) KIR3DL2 <1% (N=59) • 20.8% patients achieved Global Response, including 2 CR and 8 PR • 13.6% patients achieved Global Response, including 8 PR (95% CI 7.0, (95% CI 11.7, 3
Slide 12: TELLOMAK – Mycosis Fungoides Efficacy results: PFS
LACUTAMAB TELLOMAK – Mycosis Fungoides Efficacy results in MF patients: PFS including by KIR3DL2 Expression Level All MF KIR3DL2 ≥ 1% KIR3DL2 <1% PFS in months 10.2 12.0 8.5 Median, (95%CI) (6.5, 16.8) (5.6, 20.0) (6.5, 17.5) Alive without % (95% CI) % (95% CI) % (95% CI) progression • 6 months • 65
Slide 13: TELLOMAK – Mycosis Fungoides Patient Case
LACUTAMAB TELLOMAK – Mycosis Fungoides Patient Case Patient BASELINE Week 57 characteristics October 05, 2020 March 29, 2022 • 68-year-old female • MF diagnosed in 2016 • 4 previous lines of therapy (PUVA therapy, bexarotene, interferon, methotrexate) • T2N0M0B1 at baseline • Response: — Skin: PR fr
Slide 14: TELLOMAK data support lacutamab as a potential new SoC in MF & SS
LACUTAMAB TELLOMAK data support lacutamab as a potential new SoC in MF & SS with opportunity across patient subgroups and earlier lines of therapy KIR3DL2 enriched population Expansion All comers Line Expansion ~ 1,500 patients ~3,500 patients ~5,000 patients KIR3DL2 KIR3DL2 All Comers All Comers <1
Slide 15: ANKET®
ANKET® Eric Vivier Chief Scientific Officer 15
Slide 16: Clinical landscape of NK-cell-targeting approaches in cancer therapy
ANKET® Clinical landscape of NK-cell-targeting approaches in cancer therapy NK NK CELL CHECKPOINT NKp46 ENGAGERS INHIBITORS NK and myeloid cells CD20-IL2v IPH6501 BCMA CD16 SAR’514, IPH6401 NK and myeloid cells CD123 LILRB1 EGFR CD123 SAR’579 IPH6101 CD33 CD30 NKG2D BCMA NK and T cells NKG2A TIM3 EG
Slide 17: ANKET® NK checkpoint and engagers landscape
ANKET® NK NK CELL CHECKPOINT NKp46 ENGAGERS INHIBITORS NK and myeloid cells CD20-IL2v IPH6501 BCMA CD16 SAR’514, IPH6401 NK and myeloid cells CD123 LILRB1 EGFR CD123 SAR’579 IPH6101 CD33 CD30 NKG2D BCMA NK and T cells NKG2A TIM3 EGFR mAb-based Deciphering tetraspecific natural killer cell therapies
Slide 18: How do we elicit NK killing activity against cancer cells? ANKET®
ANKET® How do we elicit NK killing activity against cancer cells? ANKET® NK SPECIFICITY NKp46 NKp46 is the most specific activating receptor of NK cells N K p 4 6 S TAB I L I T Y CD16 Unlike many other activating receptors, TUMOR NKp46 is conserved on NK cells infiltrating solid tumors ANTIGEN S T R
Slide 19: Multiple ANKET® programs targeting hematological malignancies and solid tumors
ANKET® Multiple ANKET® programs targeting hematological malignancies and solid tumors Growing clinical pipeline FDA Fast Track Designation in AML 2023 SAR443579 / IPH6101 (CD123) Phase 1 / 2 SAR443579 progress to Ph2 in R/R AML SAR’514 / IPH6401 (BCMA) Phase 1 / 2 New Phase 1/2 in 1L AML in combinat
Slide 20: SAR'579 / IPH6101 promising preliminary single agent clinical activity in R/R AML
ANKET® ANKET® SAR'579 / IPH6101 promising preliminary single agent clinical activity in R/R AML SAR’579 (SAR443579) / IPH6101 is a trifunctional anti-CD123 NKp46-CD16 NK cell engager PHASE 1 / 2 underway in R/R AML, B-cell ALL or HR MDS Individual Patient Responses per Investigator: Dose-Escalation
Slide 21: IPH6501, a novel CD20-targeting tetraspecific NK cell engager
ANKET® IPH6501, a novel CD20-targeting tetraspecific natural killer cell engager issued from ANKET® platform, has started clinical study in B-cell malignancies Phase 1/2 first-in-human, multicenter, in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma NCT06088654 First patient dosed in M
Slide 22: IPH6501 surrogate more efficient anti-tumor activity than obinutuzumab in mice
ANKET® IPH6501 surrogate induces more efficient anti-tumor activity than obinutuzumab in a human CD20+ tumor model in mice IPH6501 increases NK cell IPH6501 controls tumor growth in vivo inflitration at tumor bed * NKp46 GzmB *** *** Vehicle IPH6501 surrogate obinutuzumab 1500 1500 1500 Tumor volume
Slide 23: IPH6501 depletes CD20+ B cells in NHP
ANKET® IPH6501 depletes CD20+ B cells in NHP Blood Secondary Lymphoid organs ✱✱✱✱ ** ** ** ✱✱✱✱ 100 ** * ✱✱✱ 75 3000 CD20+ area (% difference to vehicle) 50 Blood B cells (cell/µL) 2000 25 0 1000 -25 -50 0 -75 CD20-NKCE-IL2v (mg/kg) -100 Demaria et al., Science Immunology, in press 23
Slide 24: IPH6501 induces higher depletion of autologous B cells than T cell engager
ANKET® In samples from R/R B-NHL patients, IPH6501 induces higher depletion of autologous B cells than T cell engager (TCE) IPH6501 Epcoritamab biosimilar (CD20-TCE) Autologous B cell depletion in samples from R/R BNHL patients Autologuous B cell lysis (%) 100 100 100 Epcoritamab Unstimulated IPH650
Slide 25: IPH6501 Phase 1/2 study design in R/R CD20+ NHL
ANKET® IPH6501 Phase 1/2 study design in R/R CD20+ NHL A phase 1/2, open-label, multi-center trial investigating the safety, tolerability, and preliminary anti-neoplastic activity of IPH6501 in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma (NCT06088654) Phase 1 - Dose
Slide 26: IPH6501 potential path forward
ANKET® IPH6501 potential path forward Generate safety data and preliminary signals of activity in 2025 CD20+ B-NHL Confirm activity signal with dose optimized in CD20+ B-NHL 2026 & select B-NHL subtypes for expansion cohorts 2027 & Expansion study in selected B-NHL subtypes beyond & explore combinat
Slide 27: ADC IPH4502
ADC IPH4502 Yannis Morel Chief Operating Officer 27
Slide 28: Target Nectin-4 in a broad panel of indications on top of bladder cancer
ADC Target Nectin-4 in a broad panel of indications on top of bladder cancer OPPORTUNITIES 100 No Nectin-4 drug approved % of Nectin-4 expressing 80 • PADCEV (enfortumab vedotin, EV) is approved in bladder where expression of Nectin-4 is the tumor samples 60 highest • Relapses are frequently observe
Slide 29: IPH4502 is a novel and differentiated Nectin-4 DAR8 exatecan ADC
ADC IPH4502 is a novel and differentiated Nectin-4 DAR8 exatecan ADC Binder Payload Proprietary humanized anti- Exatecan, a Topoisomerase I Nectin-4 Antibody inhibitor • Differentiated epitope, non- • Optimal therapeutic index expected overlapping with EV (no competition for binding) • Active in EV/
Slide 30: IPH4502 shows broader and stronger efficacy than EV in multiple PDX models
ADC IPH4502 shows broader and stronger efficacy than EV in multiple PDX models from bladder cancer patients Enfortumab vedotin IPH4502 Tumor Growth Inhibition (%) Tumor Growth Inhibition (%) -80 -80 -60 -60 -40 -40 -20 -20 0 0 20 20 40 40 60 60 80 80 100 100 120 120 PD #1 PD #2 PD #3 PD #4 PD #5 PD
Slide 31: IPH4502 efficacy across Nectin-4 expression levels vs EV in bladder PDX models
ADC IPH4502 shows efficacy across various Nectin-4 expression levels & demonstrates superior activity to EV in bladder PDX models Nectin-4 expression H-score: 300 H-score: 180 H-score: 100 2000 2000 2000 Vehicle IPH4502 (4 mg/kg) Tumor volume (mm3) Tumor volume (mm3) Tumor volume (mm3) EV (4 mg/kg)
Slide 32: Nectin-4 remains highly expressed in EV-relapsed cancer patients
ADC Nectin-4 remains highly expressed in EV-relapsed cancer patients Nectin-4 expression was assessed by IHC in fresh biopsies from sites of tumor progression following EV from 3 patients Liver metastasis Lymph node metastasis Duodenal metastasis Nectin-4 expression is conserved in high grade UC pat
Slide 33: IPH4502 has anti-tumor activity in a PDX model of EV-acquired resistance
ADC IPH4502 has anti-tumor activity in a PDX model of EV-acquired resistance Generation of a PDX model of Urothelial F659 F659R cancer with EV-acquired resistance Relapsing under EV EV (4mg/kg) Tumor Volume (mm3) Tumor Volume (mm3) 2000 2000 1000 1000 0 0 0 15 30 45 0 15 30 45 Days post treatment Da
Slide 34: IPH4502 anti-tumor efficacy in PDX model beyond bladder
ADC IPH4502 shows anti-tumor efficacy in PDX model from Nectin-4+ cancer indication beyond bladder IPH45 4 mg/kg PDX model of TNBC EV 4 mg/kg IPH4502 (4 mg/kg) Treatment Vehicle TNBC Tumor volume (mm3) Nectin-4 2000 2000 H-score: 200 1000 1000 0 0 0 15 30 0 15 30 Days post treatment TNBC: triple neg
Slide 35: IPH4502 shows target-dependent bystander effect in vivo
ADC IPH4502 shows target-dependent bystander effect in vivo allowing to address Nectin-4 heterogeneous expression Nectin-4+ cells SUM190-PT cells Nectin-4+ cells Nectin-4 KO cells + Nectin-4 KO cells 1500 1500 1500 Treatment Tumor volume (mm3) 1000 1000 1000 Vehicle 500 500 500 0 0 0 20 30 40 50 60
Slide 36: IPH4502 potential path forward
ADC IPH4502 potential path forward 2024 IND cleared and generate preliminary Phase 1 safety data 2025 Establish preliminary activity signal in Nectin-4 expressing tumor types 2026 with low and high expression levels Beyond Dose optimization and exploration of combination in expansion cohorts Data wi
Slide 37: Monalizumab
Monalizumab Yannis Morel Chief Operating Officer 37
Slide 38: Monalizumab development in lung cancer
MONALIZUMAB Monalizumab development in lung cancer Phase 2 NeoCOAST Phase 2 COAST Clinical Stg I-IIIA NSCLC Unresect. Stg III NSCLC monalizumab + durvalumab monalizumab + durvalumab studies in In progress In progress Phase 2 NeoCOAST-2 Phase 3 PACIFIC-9 NSCLC 999 pts Stg II-IIIA NSCLC Unresect. Stg
Slide 39: Upcoming Catalysts & Closing Remarks
Upcoming Catalysts & Closing Remarks Arvind Sood EVP, US Operations 39
Slide 40: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts Delivering across our strategic objectives • Lacutamab TELLOMAK | end of Phase 2 FDA interaction • Lacutamab PTCL | Phase 2 Data • IPH5301 (CD73) | Phase 1 data at ESMO 2024 Proprietary • IPH6501 ANKET® (CD20 IL2v) | Phase 1 progress • IPH6501 ANKET® (CD20 IL2v) | Pha
Slide 41: Key Takeaways
Key Takeaways Create value for patients and shareholders Clinical stage company with growing differentiated first-in-class pipeline • LACUTAMAB TELLOMAK DATA • Top-line results in CTCL shared at ASCO and ASH • Regulatory strategy • EXPAND ANKET® CLINICAL PORTFOLIO – LEAD IN HEMATOLOGY INDICATIONS •
Slide 42: Q&A
B innate pharma Q&A
Slide 43: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA